AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 221 min read$CRVS

Corvus Pharmaceuticals, Inc. (CRVS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Corvus Pharmaceuticals, Inc._July 21, 2026 0001626971 false 0001626971 2026-07-21 2026-07-21 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (

Original reporting
SEC EDGAR 8-K
Published Jul 22, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 22, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$CRVS
Neutral
medium confidence
Mentioned
$CRVS
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CRVSNeutralLow
01

Why it matters

This is a governance event with a specific effective date, but the disclosure does not state strategic, financial, or regulatory causes.

02

Market read

The market may react modestly to board composition changes, but there is no new business or financial catalyst in the text.

03

What to watch

Traders may want to watch for subsequent filings that name a replacement director, committee changes, or any linked executive/officer appointments not included in this brief 8-K.

Relevance 6/10Novelty 4/10Timing: effective July 22, 2026 board resignation disclosed after-hours via 8-K

Background

The filing is an SEC Form 8-K under Item 5.02, covering director departure and related board/officer changes.

Company-level read

Ticker impact

$CRVSNeutralMedium confidence
Context

Corvus Pharmaceuticals disclosed that director Ian T. Clark will resign from its board effective July 22, 2026.

Expected impact

Likely limited near-term impact unless follow-on disclosures name a replacement or cite strategic reasons.

Evidence & confidence

The 8-K is a primary-source governance update (Item 5.02) with a stated effective date, but it does not include new guidance, financial results, or transaction terms.

Market effects

Sector

Minimal, as this is company-specific governance news with no sector-wide regulatory or clinical read-across.

Regional

Minimal, US-listed biotech governance update.

Global

Minimal, no cross-border transaction or regulatory action described.

Counterpoint

What could challenge this read

The resignation may be routine (end of term, personal reasons) and could have little bearing on the company’s pipeline or financing plans.

Key entities

  • issuer
    Corvus Pharmaceuticals, Inc.

    Nasdaq-listed company filing the 8-K; disclosed director resignation effective July 22, 2026.

  • director
    Ian T. Clark

    Board member who delivered notice of resignation effective July 22, 2026.

  • officer
    Leiv Lea

    Chief Financial Officer signing the 8-K.

Read at source← All news

Related articles

AUG 7
$CRVSMed

Corvus Pharmaceuticals Q2 Earnings Call Highlights

Corvus Pharmaceuticals (NASDAQ:CRVS) said an interim futility analysis for its PTCL Phase III trial is expected in Q1 2027, with an independent committee deciding whether to continue. Final Phase III PTCL data are still expected in late 2027. For atopic dermatitis, soquelitinib Phase I results showed EASI-75 of 75% vs 20% placebo; SIERRA-1 enrollment ends early 2027 with top-line data in Q3 2027.

yahoo.com6 min
AUG 6
$CRVSMed

Corvus Pharmaceuticals, Inc. (CRVS): Results of Operations and Financial Condition

Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopi

SEC EDGAR 8-K5 min
AUG 9
$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

rttnews.com2 min
AUG 9
$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

rte.ie6 min
AUG 9
$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

yahoo.com6 min